Vitamin K: The Nutrient New Zealand Labels Rarely Explain
Vitamin K sits quietly in green vegetables, newborn injections, and calcium-plus-K2 supplement blends, yet most shoppers never learn that K1 and K2 do different jobs or why warfarin users are told to keep their vegetable intake steady rather than low. Here is what the two forms actually do, what the bone and heart research supports, and how to read a New Zealand supplement label before adding another capsule.
Only Health Editorial Team
August 24, 2026
A green smoothie, a calcium-and-K2 capsule, and a newborn injection can all involve vitamin K. They do not mean the same thing. The label often compresses phylloquinone, menaquinone, MK-4 and MK-7 into a small line of micrograms, then lets bone or heart imagery do the rest of the selling.
That shortcut is a problem when a person takes warfarin, is considering a high-dose K2 product, or assumes a supplement can replace a varied diet. Vitamin K is essential. It also has a medication interaction important enough that a sudden change in intake can matter. A useful label-reading habit starts by separating what is established from what is still being tested.
The vitamin behind a very specific letter
Vitamin K is a family of fat-soluble compounds rather than one single substance. The “K” comes from the German word Koagulation, reflecting the nutrient’s original connection with blood clotting. The National Institutes of Health Office of Dietary Supplements (NIH ODS) describes vitamin K as a cofactor for an enzyme that activates proteins involved in haemostasis, bone metabolism and other processes.
The best-known clotting protein in this story is prothrombin, also called clotting factor II. The body needs vitamin-K-dependent reactions to make several clotting factors work as intended. That does not mean more supplemental vitamin K produces “better” clotting in a healthy adult. It means the nutrient is part of a tightly controlled system. The same system explains why vitamin K deserves extra care when a person uses an anticoagulant such as warfarin.
Vitamin K-dependent proteins are also found outside the liver. Osteocalcin is present in bone. Matrix Gla protein is found in vascular smooth muscle, cartilage and bone, where it has become a focus of research into abnormal calcification. These biological details make a plausible starting point for K2 marketing, but biology is not the same as proof that a capsule prevents fractures, heart attacks or artery disease.
For everyday eating, the starting point is less dramatic. Vitamin K occurs naturally in food, and deficiency is uncommon in healthy adults who eat a varied diet. The question a label should help answer is not “is vitamin K good?” It is: which form, how much, why is it included, and does it fit with medicines or a clinician’s advice?
K1 and K2 are not interchangeable label shorthand
Phylloquinone is usually called vitamin K1. It is the principal dietary form and is concentrated in green leafy vegetables. Spinach, kale, broccoli and lettuce are familiar sources. Vegetable oils contribute too. Menaquinones are grouped under vitamin K2. They are found in smaller amounts in some animal foods and fermented foods, and are identified by names such as MK-4, MK-7 and MK-9.
The difference matters because a product labelled “K2” still leaves a reader with questions. MK-4 and MK-7 are not just two spellings for the same ingredient. They are different menaquinones. NIH ODS notes that MK-4, MK-7 and MK-9 are among the most studied forms. It also notes that, in one study, phytonadione and MK-7 were both well absorbed, while MK-7 had a longer half-life. That finding does not establish that one form is the right supplement for everyone.
A label may also use phytonadione, a synthetic form of K1, or list a menaquinone without making its MK number prominent. Read the ingredient panel rather than relying on a front-of-pack phrase such as “bone support.” A calcium product can contain vitamin D, K1, K2, magnesium or several of them. Those nutrients have distinct evidence bases and distinct reasons for inclusion.
Food patterns add another wrinkle. Green vegetables mainly provide K1. Fermented and animal foods can provide some menaquinones, but the amount varies with the food and preparation. Natto, a fermented soybean dish common in parts of Japan, is frequently cited as one of the richest dietary sources of MK-7, far beyond what a typical New Zealand diet supplies from cheese, egg yolk or meat. That is one reason population studies from Japan feature heavily in the K2 research literature, and why findings from that setting do not automatically transfer to a New Zealand shopper eating a very different diet. The gut microbiome produces menaquinones too, although that fact does not give a consumer a practical way to calculate their intake. It is a reason to avoid turning a complicated nutrient system into a single marketing score.
It is also worth separating supplement marketing from pharmacology. Menaquinones with longer isoprenoid side chains, such as MK-7, tend to stay in the bloodstream longer than phylloquinone, which is one argument supplement companies use for dosing K2 less frequently or at a lower daily amount than K1. A longer half-life is a pharmacokinetic property, not proof of a larger health benefit. It changes how a nutrient behaves in the body; it does not by itself change what a shopper should expect it to do for bone or heart outcomes.
The amount on the panel needs context
Vitamin K amounts are printed in micrograms, written as mcg or µg. That is one-millionth of a gram. Microgram units can make a number look small even when it is far above a general dietary target, so compare the panel with an established reference rather than judging the number by appearance.
NIH ODS lists adequate-intake values of 120 mcg a day for adult men aged 19 and older, and 90 mcg a day for adult women aged 19 and older. The same 90 mcg figure is listed for pregnant and breastfeeding adult women. These are intake targets, not a prescription to take a supplement. They also do not separate K1 from K2 in the way supplement advertising often does.
Unlike several nutrients, vitamin K does not have a tolerable upper intake level set by NIH ODS. That absence should not be translated into “any dose is harmless” or “more is better.” An upper limit is not the only safety consideration. Medication interactions, the purpose of a formula, a person’s health history, and duplicated ingredients across several products still matter.
Some multivitamin-mineral products contain vitamin K at values below 75% of the daily value, according to NIH ODS. Stand-alone products and blends with calcium, magnesium or vitamin D can contain much more. A buyer who takes a multivitamin, a bone formula and a greens powder can easily miss that vitamin K appears in more than one place.
A practical reading sequence is:
- Find the vitamin K line in every regular supplement, not just the newest bottle.
- Record the amount per daily serving, not merely per capsule.
- Check whether the ingredient is K1, MK-4, MK-7 or an unspecified menaquinone.
- Add the stated daily totals only after checking how many tablets or scoops the label defines as one serving.
- If warfarin or another medicine is involved, take the list to the prescriber or pharmacist before changing the routine.
This is label literacy, not self-diagnosis. It makes the conversation with a clinician more accurate.
Food is the ordinary route for most adults
The consumer fact sheet from NIH ODS lists leafy vegetables, vegetable oils, some fruits, meat, cheese, eggs and soybeans among food sources of vitamin K. A mixed diet does not require a person to identify every microgram on the plate. It does call for recognising that vegetables are nutrient-dense foods, not an obstacle to be removed because vitamin K has an interaction with one medicine.
The food-first point has an important boundary. People using warfarin should not make abrupt changes to their vitamin K intake without clinical advice. That is a consistency issue, not a command to avoid leafy greens. The Heart Foundation of New Zealand explains it plainly: aim to eat similar amounts of vitamin-K-containing foods each week so blood vitamin K is fairly constant and INR is more likely to remain stable.
What’s most important is that you aim to eat similar amounts of these foods each week. — Heart Foundation of New Zealand
The distinction is easy to miss. A person who ordinarily eats broccoli, silverbeet or salad can usually work with their clinical team to keep that pattern steady. The bigger risk is swinging from none to large serves, or starting a concentrated supplement, without factoring the change into warfarin management. Stopping vegetables altogether can make a diet poorer in fibre and other nutrients while failing to solve the real problem.
For someone not taking warfarin, food remains the benchmark because it brings more than vitamin K. It provides fibre, potassium, folate and a range of other compounds. A capsule may be appropriate in a specific plan, but it should not inherit the nutritional halo of a plate of vegetables.
Why newborn vitamin K is a different conversation
Vitamin K is often discussed in New Zealand at the beginning of life, not in a supplement aisle. Newborn babies have low vitamin K levels. They have little gut bacteria at birth, receive limited vitamin K transfer before birth, and breast milk does not contain enough to provide protection on its own. The concern is vitamin K deficiency bleeding (VKDB), a rare but potentially serious bleeding disorder.
Healthify New Zealand states that a single vitamin K injection at birth is the most effective way to prevent VKDB. Its guidance explains that bleeding can be internal and can result in permanent brain damage or death. Babies born early, babies who are sick, babies whose mothers use some medicines, and exclusively breastfed babies who did not receive vitamin K at birth can face increased risk.
Medsafe’s published consensus statement supports vitamin K for all babies to prevent VKDB and identifies the intramuscular route as preferred. That document dates from 2001 and carries an age notice on the Medsafe site, so families should use their current midwife, maternity service or paediatric clinician for present-day advice. The core point is stable: newborn prophylaxis is a medical prevention measure, not a wellness trend and not evidence that adults need large K2 doses.
It is also not sensible to compare the newborn injection dose or route with an adult supplement. They address different circumstances, different risks and different clinical decisions. A social-media post that turns them into one argument removes the details that make either conversation safe.
Bone claims deserve a narrower reading
Vitamin K participates in bone-related proteins, and that is why it appears beside calcium and vitamin D in bone products. The scientific question is more precise than “does K2 help bones?” Researchers have studied different forms, doses, populations, outcomes and follow-up periods. Bone mineral density, biochemical markers and fracture rates are not interchangeable outcomes.
NIH ODS gives a restrained consumer summary: some studies find that vitamin K supplements improve bone strength and reduce fracture risk, while others do not; more research is needed to understand whether supplementation improves bone health or reduces osteoporosis risk. That is a better summary for a shopper than a bottle claiming certainty.
A 2024 systematic review and meta-analysis in Bone & Joint Research reported positive effects of vitamin K, particularly K2, on lumbar-spine bone mineral density in middle-aged and older adults. Its authors also reported no effect on several other bone metabolism measures. The result is useful, but it does not turn a K2 supplement into a substitute for assessment and treatment of osteoporosis risk.
Bone health decisions have larger foundations: adequate dietary intake, resistance and weight-bearing activity where appropriate, avoiding smoking, moderation with alcohol, fall prevention, and medical assessment when risk factors or fractures are present. A clinician may consider bone density testing, medicines or a specific nutrient plan. One nutrient line on a label cannot do all of that work.
For a shopper comparing products, the honest claim is modest. K2 is being studied in bone health. Some evidence is promising for particular outcomes and populations. The answer to whether a person should take it depends on their diet, medicines, risk profile and clinician’s advice, not a generic image of a strong skeleton.
Artery imagery goes further than current proof
Vitamin K2 is also marketed with language about directing calcium to bones and away from arteries. There is a biological basis for studying this area: matrix Gla protein is vitamin-K-dependent and is involved in research on calcification. But a mechanism is not a clinical outcome. It does not establish that a retail K2 product prevents cardiovascular disease.
This distinction is especially important when a label carries a heart icon or words such as “vascular support.” The term can sound like a treatment promise even when the underlying studies measure a surrogate marker, not heart attack, stroke or mortality. Consumers should ask what the product is claiming and whether that claim is supported by a trial in people like them.
NIH ODS does not advise vitamin K supplementation as a proven strategy to prevent cardiovascular disease. Its fact sheet describes the relevant proteins and the research interest, while maintaining the difference between physiological roles and tested health outcomes. That restraint is valuable. It protects people from treating a supplement as an alternative to blood-pressure care, cholesterol management, diabetes care, smoking cessation or prescribed medication.
The same caution applies to a calcium supplement paired with K2. Calcium, vitamin D and K2 may be present in one product, but their presence together does not prove that the blend has a unique outcome. Check each ingredient, each dose, and the reason it was selected. If the reason is a diagnosed condition, a pharmacist or clinician should be part of the decision.
Warfarin changes the rule from more to steady
Warfarin works by antagonising vitamin K activity. This makes vitamin K one of the most important diet-and-medicine interactions to understand correctly. NIH ODS says people taking warfarin should maintain consistent vitamin K intake. Its consumer guidance warns that a sudden decrease can increase dangerous bleeding risk and a sudden increase can increase clot risk.
The word “consistent” applies to food and supplements. Starting an MK-7 supplement, stopping a multivitamin that contains K1, changing a greens powder, or dramatically changing weekly vegetable intake can all be relevant. A person should not make those adjustments independently and then wait for a routine INR test to reveal the effect.
Illness adds a further layer that is easy to overlook. A stomach bug that cuts food intake for several days, a course of antibiotics, or a temporary switch to a very different diet while travelling can all shift vitamin K intake without a person deciding to change anything. Anyone on warfarin who has been eating far less than usual, or who has started or stopped antibiotics, has a genuine reason to mention it at their next INR check rather than assuming the fluctuation will sort itself out.
This does not mean every anticoagulant has the same interaction profile. Medication names and advice differ. The safe move is to tell the pharmacist, nurse or prescriber the exact product name, form and dose, including non-prescription supplements. Bring the bottle or a clear photo of the full panel. “I take a bone vitamin” is less useful than “I take 180 mcg MK-7 daily in this calcium product.”
Other medicines can affect vitamin K status or absorption. NIH ODS names long-term antibiotics, bile-acid sequestrants such as cholestyramine and colestipol, and the weight-loss medicine orlistat as examples requiring attention. That does not establish a problem for every user. It is a reminder that absorption, diet and medicine routines belong in the same conversation.
New Zealand regulation is not a clinical endorsement
In New Zealand, dietary supplements are regulated under the Dietary Supplements Regulations 1985, which sit under the Food Act 2014. Medsafe administers the dietary supplement regulations, while the Ministry for Primary Industries administers the Food Act. Medsafe says the regulations cover requirements including labelling and maximum permitted daily doses for several vitamins and minerals.
A compliant-looking package is not a personal recommendation. Regulation and product quality matter, but they do not replace an individual assessment of interactions, symptoms or the suitability of a claim. A supplement should not be used to diagnose, treat or manage a condition when clinical care is needed.
There is a second label issue: products can be sold in different categories and the wording used to market them can shape expectations. A general wellness product is not automatically equivalent to a medicine that has been assessed for a therapeutic indication. When the marketing language sounds like a promise to treat osteoporosis, artery disease or a bleeding disorder, pause before buying.
A clear label should make the daily serving, the vitamin K form and the amount understandable. If it does not, ask the seller or manufacturer for the full ingredient information. If you are taking medicines, do not use missing detail as a reason to guess.
A careful way to compare a K2 product
A supplement comparison can be practical without pretending that every shopper needs one. Start with the reason you are considering vitamin K. “Because it was bundled with calcium” is different from following a dietitian’s plan after a documented nutrition issue. The reason determines what questions matter next.
Use this short checklist when a product says K2, MK-7 or bone support:
- Identify the exact form. Does the panel say K1, MK-4, MK-7 or simply vitamin K?
- Check the amount per full daily serving. Do not compare a one-capsule figure with a label that directs two capsules daily.
- Look for duplicate vitamin K in multivitamins, calcium blends, greens powders and meal replacements.
- Review medicines first, especially warfarin. Do not begin, stop or change vitamin K intake without the clinician who manages it.
- Treat heart and bone imagery as marketing context, not proof of a personal clinical benefit.
- Prefer a product whose full panel you can read over one that hides behind a proprietary blend.
The same approach helps with side effects and symptoms. Unexpected bruising, bleeding, weakness, pain, a fall or a possible fracture calls for healthcare advice, not a self-directed adjustment to vitamins. A supplement label cannot distinguish a mild dietary question from a problem needing prompt assessment.
What to take from the label, and what to leave there
Vitamin K earns its place in nutrition because it is necessary for normal clotting and is involved in bone-related proteins. Green vegetables are a normal source of K1. K2 is a family of menaquinones that appears in some foods and supplements. Those are solid starting facts.
The leap from those facts to a universal K2 routine is where reading becomes important. Evidence for bone outcomes is still mixed and context-specific. Research into vascular calcification is scientifically interesting, but it does not make a capsule a replacement for cardiovascular care. Newborn vitamin K protects against a specific medical risk and should not be repurposed as advertising for adult products.
For most people, the useful action is simple: eat a varied diet, read the actual panel when buying a blend, and include medicines in the conversation. For anyone on warfarin, the rule is sharper: keep vitamin K intake steady and discuss any food or supplement change with the clinical team managing the prescription. That is more protective than a front-label promise.
Sources: NIH Office of Dietary Supplements, Vitamin K fact sheets for consumers and health professionals; Medsafe New Zealand; Healthify New Zealand; Heart Foundation of New Zealand; Bone & Joint Research systematic review and meta-analysis.
Sources
This article is for general education and does not replace advice from a qualified healthcare professional.
Keep reading
Vitamin E: What the IU on the Label Actually Means
By Only Health Editorial Team
Vitamin E bottles still mix IU and milligrams, natural and synthetic forms, and antioxidant marketing that outruns the evidence. Here is what alpha-tocopherol actually does, why the SELECT trial changed how researchers view high-dose vitamin E, and how to read a New Zealand label before you add another capsule to your routine.
Vitamin B6: What the Label Doesn't Warn You About
By Only Health Editorial Team
Vitamin B6 sits quietly in magnesium blends, energy formulas and multivitamins, and most buyers never add up the milligrams. Here is what pyridoxine actually does, why regulators in New Zealand and Australia have both tightened the rules on it, and how to read a label before symptoms show up in your hands and feet.
Probiotics on the Label: CFU, Strains, and What the Evidence Actually Supports
By Only Health Editorial Team
A probiotic label can list a Latin name, a strain code, and a CFU count in the billions. Here is what those details actually mean, what the human trials show for common gut symptoms, and how to read a New Zealand supplement claim without overpaying for a number.
Discussion
Share your thoughts, questions, or experience so other readers can learn from your routine.
0 comments
to join the conversation.
No comments yet.
